Company intelligence / Profile preview

Foreland Pharma

Beijing, Beijing Shi, Chinaconvention.bio.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Foreland Pharma’s lead asset FP‑208, a dual PI3K/mTOR inhibitor, has completed a Phase I clinical trial evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. The study confirmed safety and provided initial signals of anti-tumor activity. Another program targeting Sphingosine 1-phosphate receptors (FP‑253/FP‑264) remains at the preclinical stage.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Foreland Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foreland Pharma.

Explore the full profile